Clinical Trials · NCT04965506
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 252
- Start date
- Sep 2021
- Locations
- 1 site, China
- Primary endpoint
- The change in HbA1c from baseline to 20 weeks